These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 34799647)

  • 41. Prognostic role of KL-6 in SSc-ILD patients with pleuroparenchymal fibroelastosis.
    d'Alessandro M; Bellisai F; Bergantini L; Cameli P; D'Alessandro R; Mazzei MA; Gentili F; Conticini E; Selvi E; Frediani B; Matucci-Cerinic M; Bargagli E
    Eur J Clin Invest; 2021 Aug; 51(8):e13543. PubMed ID: 33759179
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum KL-6 levels predict clinical outcomes and are associated with
    Azekawa S; Chubachi S; Asakura T; Namkoong H; Sato Y; Edahiro R; Lee H; Tanaka H; Otake S; Nakagawara K; Fukushima T; Watase M; Sakurai K; Kusumoto T; Masaki K; Kamata H; Ishii M; Hasegawa N; Okada Y; Koike R; Kitagawa Y; Kimura A; Imoto S; Miyano S; Ogawa S; Kanai T; Fukunaga K;
    BMJ Open Respir Res; 2023 May; 10(1):. PubMed ID: 37230764
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Krebs von den Lungen-6 levels in untreated idiopathic pulmonary fibrosis.
    Jiang D; Xiao H; Dong R; Geng J; Xie B; Ren Y; Dai H
    Clin Respir J; 2022 Mar; 16(3):234-243. PubMed ID: 35081277
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.
    Elhai M; Hoffmann-Vold AM; Avouac J; Pezet S; Cauvet A; Leblond A; Fretheim H; Garen T; Kuwana M; Molberg Ø; Allanore Y
    Arthritis Rheumatol; 2019 Jun; 71(6):972-982. PubMed ID: 30624031
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diagnostic and prognostic predictive values of circulating KL-6 for interstitial lung disease: A PRISMA-compliant systematic review and meta-analysis.
    Zhang H; Chen L; Wu L; Huang J; Li H; Wang X; Weng H
    Medicine (Baltimore); 2020 Apr; 99(16):e19493. PubMed ID: 32311922
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Improving risk-stratification of rheumatoid arthritis patients for interstitial lung disease.
    Avouac J; Cauvet A; Steelandt A; Shirai Y; Elhai M; Kuwana M; Distler O; Allanore Y
    PLoS One; 2020; 15(5):e0232978. PubMed ID: 32384128
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Analytical and Clinical Performance of the Nanopia Krebs von den Lungen 6 Assay in Korean Patients With Interstitial Lung Diseases.
    Cho EJ; Park KJ; Ko DH; Koo HJ; Lee SM; Song JW; Lee W; Lee HK; Do KH; Chun S; Min WK
    Ann Lab Med; 2019 May; 39(3):245-251. PubMed ID: 30623616
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expression of S100A9 and KL-6 in common interstitial lung diseases.
    Lin L; Zhao Y; Li Z; Li Y; Wang W; Kang J; Wang Q
    Medicine (Baltimore); 2022 Apr; 101(17):e29198. PubMed ID: 35512076
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Krebs von den Lungen-6 as a Potential Predictive Biomarker in Fibrosing Interstitial Lung Diseases.
    Lederer C; Mayer K; Somogyi V; Kriegsmann K; Kriegsmann M; Buschulte K; Polke M; Findeisen P; Herth F; Kreuter M
    Respiration; 2023; 102(8):591-600. PubMed ID: 37586349
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Changes of serum Krebs von den Lungen-6 levels in interstitial lung disease associated with dermatomyositis and secondary Sjögren's syndrome: a case report].
    Yu JF; Jin YB; He J; An Y; Li ZG
    Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Oct; 49(5):910-914. PubMed ID: 29045979
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study.
    Chen F; Lu X; Shu X; Peng Q; Tian X; Wang G
    Intern Med J; 2015 Jun; 45(6):641-7. PubMed ID: 25827843
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Elevated Serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease.
    Kuwana M; Shirai Y; Takeuchi T
    J Rheumatol; 2016 Oct; 43(10):1825-1831. PubMed ID: 27481907
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of the clinical performance of the HISCL-5000 analyzer in the detection of Krebs von den Lungen-6 antigen and its diagnostic value in interstitial lung disease.
    Wang J; Huang Z; Xue M; Huang H; Zheng X; Zhong N; Sun B
    J Clin Lab Anal; 2020 Feb; 34(2):e23070. PubMed ID: 31691368
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Correlation between CT-based phenotypes and serum biomarker in interstitial lung diseases.
    Shin B; Oh YJ; Kim J; Park SG; Lee KS; Lee HY
    BMC Pulm Med; 2024 Oct; 24(1):523. PubMed ID: 39427156
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Could KL-6 levels in COVID-19 help to predict lung disease?
    Frix AN; Schoneveld L; Ladang A; Henket M; Duysinx B; Vaillant F; Misset B; Moutschen M; Louis R; Cavalier E; Guiot J
    Respir Res; 2020 Nov; 21(1):309. PubMed ID: 33234132
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of molecular structural variants on serum Krebs von den Lungen-6 levels in sarcoidosis.
    Shigemura M; Nasuhara Y; Konno S; Shimizu C; Matsuno K; Yamguchi E; Nishimura M
    J Transl Med; 2012 Jul; 10():111. PubMed ID: 22650152
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Diagnostic Performance of CLEIA Versus FEIA for KL-6 Peripheral and Alveolar Concentrations in Fibrotic Interstitial Lung Diseases: A Multicentre Study.
    d'Alessandro M; Gangi S; Paggi I; Soccio P; Bergantini L; Pianigiani T; Montuori G; Moriondo G; Natalello G; Marrucci S; Brogna A; Scioscia G; Lacedonia D; Cameli P; Bargagli E
    J Clin Lab Anal; 2024 Oct; 38(19-20):e25108. PubMed ID: 39323282
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CA 15 - 3 in screening for systemic autoimmune rheumatic disease associated interstitial lung disease: a single center cross-sectional study.
    Frketic Marovic K; Kardum Z; Sahinovic I; Tolic A; Kasap Basioli E; Patrk J; Mayer M
    Rheumatol Int; 2024 Oct; 44(10):2017-2025. PubMed ID: 39180532
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung disease.
    Kawase S; Hattori N; Ishikawa N; Horimasu Y; Fujitaka K; Furonaka O; Isobe T; Miyoshi S; Hamada H; Yamane T; Yokoyama A; Kohno N
    Respir Res; 2011 Jul; 12(1):97. PubMed ID: 21791074
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
    Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H
    BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.